Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06171399 · ClinicalTrials.gov registry record · NA
Cannabis Edibles Packaging Descriptors Experiment
A NA study of Cannabis Use, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- NA
- Development phase
- 2,521
- Enrollment target
- 1
- Study location
NCT06171399: Completed NA study of Cannabis Use, sponsored by Wake Forest University Health Sciences.
NCT06171399 is a NA study of Cannabis Use that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 2,521 participants, above the 222-participant average among 44 other Cannabis Use trials with a reported enrollment target (1036% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06171399, a NA study of Cannabis Use, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 2,521 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess differences in perceptions of product appeal, harm, and subsequent willingness to try cannabis edibles products with/without product descriptors of interest.
Primary Outcome
One item to assess the appeal of the product. Results will be reported as mean for all products within condition. Question: How appealing is this product to you? Response Options: (0) Not at all appealing to (10) Very appealing
Conditions Studied
Interventions
- BEHAVIORAL "All Natural" descriptor
- BEHAVIORAL "Gluten-free" descriptor
- BEHAVIORAL "Vegan" descriptor
- BEHAVIORAL "100% Organic" descriptor
- BEHAVIORAL "Handcrafted" descriptor
Study Locations (1)
North Carolina
- Wake Forest University Health Sciences - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,521 participants |
| Start Date | 2024-03-15 |
| Est. Completion | 2024-04-15 |
| Phase | NA |
What the finished NCT06171399 record still lists
NCT06171399 is an interventional study that assigns participants to a tested intervention. Its 2,521 participants enrollment target places it among the larger protocols in the corpus, above the 222-participant average among 44 other Cannabis Use trials with a reported enrollment target (1036% higher).
The record links to 1 condition, with Cannabis Use appearing as the primary indexed condition, and to 5 interventions - of which "All Natural" descriptor is the first listed.
NCT06171399 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT06171399 about?
NCT06171399 is a clinical study titled "Cannabis Edibles Packaging Descriptors Experiment". The purpose of this study is to assess differences in perceptions of product appeal, harm, and subsequent willingness to try cannabis edibles products with/without product descriptors of interest.
What is the current status of trial NCT06171399?
This trial is currently completed. It is a NA study. The enrollment target is 2,521 participants. The study started on 2024-03-15. Estimated completion is 2024-04-15.
What conditions does trial NCT06171399 study?
This clinical trial studies the following conditions: Cannabis Use.
What interventions are being tested in trial NCT06171399?
The interventions under investigation include: "All Natural" descriptor (BEHAVIORAL), "Gluten-free" descriptor (BEHAVIORAL), "Vegan" descriptor (BEHAVIORAL), "100% Organic" descriptor (BEHAVIORAL), "Handcrafted" descriptor (BEHAVIORAL).
Who is sponsoring clinical trial NCT06171399?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06171399 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cannabis Use
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06171399's enrollment target sits among peer trials
2,521 1st of 44 higher than 44 of 44 other Cannabis Use trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cannabis Use trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Feasibility/Acceptability of a Brief Motivational Intervention for Frequent/High-Intensity Cannabis Use
RECRUITING · NA
-
Distinguishing Alcohol Intoxication, Cannabis Intoxication and Co-intoxication Using Electroencephalography (EEG)
RECRUITING · NA
-
Mobile Intervention for Simultaneous Alcohol and Marijuana Use in Young Adults
RECRUITING · NA
-
Precision Brain Stimulation to Reduce Cannabis Craving in Schizophrenia
RECRUITING · NA
-
Cannabis THC Potency, Metabolism, and Cognitive Impairment in Young Adults
RECRUITING · NA
-
Stress and Resilience
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04142177 · 2,529 participants · NA
Sequential and Comparative Evaluation of Pain Treatment Effectiveness Response
- NCT00018057 · 2,530 participants · Phase 2
Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders
- NCT05931276 · 2,540 participants · Phase 3
CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes
- NCT00001160 · 2,500 participants
Studies on Tumors of the Thyroid
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI